Study design
This phase 2 and 3 study was performed at 67 centers in China between 11 November 2020 and 28 September 2022. This clinical trial included phase II single-arm study and a phase III randomized controlled study. The phase II study…
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
